Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 521

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Open access
Mendoza, Pilar, Gruell, Henning, Nogueira, Lilian, Pai, Joy A., Butler, Allison L., Millard, Katrina, Lehmann, Clara, Suárez, Isabelle, Oliveira, Thiago Y., Lorenzi, Julio C. C., Cohen, Yehuda Z., Wyen, Christoph, Kümmerle, Tim, Karagounis, Theodora, Lu, Ching-Lan, Handl, Lisa, Unson-O’Brien, Cecilia, Patel, Roshni, Ruping, Carola, Schlotz, Maike, Witmer-Pack, Maggi, Shimeliovich, Irina, Kremer, Gisela, Thomas, Eleonore, Seaton, Kelly E., Horowitz, Jill, West, Anthony P., Bjorkman, Pamela J., Tomaras, Georgia D., Gulick, Roy M., Pfeifer, Nico, Fätkenheuer, Gerd, Seaman, Michael S., Klein, Florian, Caskey, Marina, Nussenzweig, Michel C.·2018·Nature
DOI 10.1038/s41586-018-0531-2
Open this paper in CoChat — free account

Abstract

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that target independent sites on the HIV-1 envelope spike, was administered during analytical treatment interruption. Participants received three infusions of 30 mg kg−1 of each antibody at 0, 3 and 6 weeks. Infusions of the two antibodies were generally well-tolerated. The nine enrolled individuals with antibody-sensitive latent viral reservoirs maintained suppression for between 15 and more than 30 weeks (median of 21 weeks), and none developed viruses that were resistant to both antibodies. We conclude that the combination of the anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 can maintain long-term suppression in the absence of antiretroviral therapy in individuals with antibody-sensitive viral reservoirs. Combination therapy with the anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 maintains long-term suppression in the absence of antiretroviral therapy in individuals with antibody-sensitive viral reservoirs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-018-0531-2

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 521

Metadata

Authors
Mendoza, P., Gruell, H., Nogueira, L., Pai, J. A., Butler, A. L., Millard, K., Lehmann, C., Suárez, I., Oliveira, T. Y., Lorenzi, J. C. C., Cohen, Y. Z., Wyen, C., Kümmerle, T., Karagounis, T., Lu, C.-L., Handl, L., Unson-O’Brien, C., Patel, R., Ruping, C., Schlotz, M., Witmer-Pack, M., Shimeliovich, I., Kremer, G., Thomas, E., Seaton, K. E., Horowitz, J., West, A. P., Bjorkman, P. J., Tomaras, G. D., Gulick, R. M., Pfeifer, N., Fätkenheuer, G., Seaman, M. S., Klein, F., Caskey, M., & Nussenzweig, M. C.
Venue
Nature
Publisher
Springer Science and Business Media LLC
Published
2018-09-26
Volume
561
Issue
7724
Pages
479-484
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
DOI
10.1038/s41586-018-0531-2
OpenAlex
W2890205877
Cited by
521
References
51
FWCI
29.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination therapy with anti-HIV-1 antibodies maintains viral suppression. https://app.cochat.ai/papers/10.1038/s41586-018-0531-2
The paper
Mendoza, P., Gruell, H., Nogueira, L., Pai, J. A., Butler, A. L., Millard, K., Lehmann, C., Suárez, I., Oliveira, T. Y., Lorenzi, J. C. C., Cohen, Y. Z., Wyen, C., Kümmerle, T., Karagounis, T., Lu, C.-L., Handl, L., Unson-O’Brien, C., Patel, R., Ruping, C., . . . Nussenzweig, M. C. (2018). Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. https://doi.org/10.1038/s41586-018-0531-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.